A male patient aged 67 who complaints of slight fever and sputum in August 2008 was hospitalized for a thorough examination and then diagnosed as a case of limited small cell lung cancer. For treatment, Irinotecan (60 mg/m2) and Cisplatin (60 mg/m2) were administered 12 times, and, at the same time, oncothermia was given 24 times (2 cycles) totally, 2 times per week. Then, chest PA and chest CT found that he was in complete remission from small cell lung cancer. So, treatments of chemotherapy and oncothermia were stopped from October 2009 and then he was in outpatient follow-up on a regular basis. On October 25th, 2010, PET CT showed a normal finding.
In April 2011 he was treated by chemotherapy for prostatomegaly. Because PSA was increased to 4.96 in June 2011, he got a prostate tissue biopsy and was diagnosed as a case of adenocarcinoma. Finally, he was treated by the prostate cancer resection using the Da Vinci robot at July 2011. Chest CT in July 2011 found mediastinal lymphadenopathy, and, after mediastinoscopy, he was diagnosed as a case of metastatic small cell lung cancer. Forchemotherapy, Etoposide (110 mg/m2) and Cisplatin (70 mg/m2) were 12 times administered in replacement, and another one-cycle treatment of oncothermia was given.
In December 2011 and February and April 2012, follow-up chest CT found the patient was in complete remission. During out- patient follow-ups in September 2012, chest CT found multiple nodes in the left upper and lower lobes on possible suspicion of metastasis. Under the patient’s personal circumstances including general weakness, chemotherapy and endothermic were stopped, and he is now observed in outpatient follow-up for more than 3 years.
Three months later, the checkup had shown good partial remission (PR) on the lesion; patient is free from symptoms.
The small-cell lung cancer cases were treated in a combination of chemotherapy and radiation therapy, with complementary oncothermia.
7 out of 8 cases in control arm who underwent only chemotherapy. The active arm, the combination of chemotherapy and oncothermia treatment, had 23 patients.
Anticancer drug in first line was Irinotecan (60 mg/m2) and Cisplatin (60 mg/m2) three times after chest CT was taken. When the progression of tumor or metastases were detected we replaced the chemotherapy regime by Etoposide (110 mg/m2) and Cisplatin (70 mg/m2) in second line.
Oncothermia was performed from the first anticancer drug treatment period up to 150-Watt, 1490.5 kJ energy by 60 minutes, every second day, with rise in temperature to 38.5∘C to 42.5∘C. In this study they used electrode 30 cm diameter applied for thorax.
• Chemotherapy alone (without oncothermia) was applied for eight cases. The survival time ranged from 2 months up to 29 months. At the combination of chemotherapy and oncothermia, the survival time was from 2 months up to 36 months.
• All other 31 patients underwent chemotherapy and 23 had combined treatment with oncothermia.
• Among 23 cases, one case died within one month after the date of diagnosis, who had been treated by chemotherapy only. Cases who have survived more than 3 years were 3, all of whom have been treated by the combined use of chemotherapy and oncothermia.
• Out of 31 cases, 14 cases died during the treatment: (i) 7 cases with chemotherapy only, including one long survival case of 28 months, and (ii) 7 cases treated by the combined use of chemotherapy and oncothermia, including one long survival case of 26 months.
• Out of 31 cases, 16 cases are alive up to the present: 4 cases with chemotherapy only, including one long survival case of 28.7 months, and (ii) cases treated by the combined use of chemotherapy and oncothermia, including three long survival cases of more than 3 years.
• The combined use of chemotherapy and oncothermia has signicantly enhanced the survival rate in comparison with the use of chemotherapy only (𝑃 value = 0.0200).
In all the cases of small cell lung cancer, we obtained a better treatment efficacy than the treatment of chemotherapy only, by the combined use of chemotherapy and oncothermia. The combined use of oncothermia can enhance the treatment efficacy of chemotherapy, thus getting a higher rate of survival against small cell lung cancer. Results show promising improvement of the survival compared to chemotherapy alone.
Article Reference link: click here
Scientific article publishing date : 18/1/2013
Immucura identifier : BSC21_043EN